PALO ALTO, Calif., Nov. 14, 2023 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2023 . “We have three retinal disease prospects in our pipeline: two molecules built with our antibody biopolymer conjugate platform (ABC Platform), (1) tarcocimab…Read More
Kodiak Sciences Inc Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights
